Search

Your search keyword '"Sayer, Herbert"' showing total 212 results
Start Over Author "Sayer, Herbert" Publication Type Academic Journals
212 results on '"Sayer, Herbert"'

2. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Author

Niederwieser, Dietger, Lang, Thomas, Krahl, Rainer, Heinicke, Thomas, Maschmeyer, Georg, Al-Ali, Haifa Kathrin, Schwind, Sebastian, Jentzsch, Madlen, Cross, Michael, Kahl, Christoph, Wolf, Hans-Heinrich, Sayer, Herbert, Schulze, Antje, Dreger, Peter, Hegenbart, Ute, Krämer, Alwin, Junghanss, Christian, Mügge, Lars-Olof, Hähling, Detlev, Hirt, Carsten, Späth, Christian, Peter, Norma, Opitz, Bernhard, Florschütz, Axel, Reifenrath, Kolja, Zojer, Niklas, Scholl, Sebastian, Pönisch, Wolfram, Heyn, Simone, Vucinic, Vladan, Hochhaus, Andreas, Aul, Carlo, Giagounidis, Aristoteles, Balleisen, Leopold, Oldenkott, Bernd, Staib, Peter, Kiehl, Michael, Schütte, Wolfgang, Naumann, Ralph, Eimermacher, Hartmut, Dörken, Bernd, Sauerland, Cristina, Lengfelder, Eva, Hiddemann, Wolfgang, Wörmann, Bernhard, Müller-Tidow, Carsten, Serve, Hubert, Schliemann, Christoph, Hehlmann, Rüdiger, Berdel, Wolfgang E., Pfirrmann, Markus, Krug, Utz, and Hoffmann, Verena S.

Published
2023
Full Text
View/download PDF

5. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Author

Heinicke, Thomas, Krahl, Rainer, Kahl, Christoph, Cross, Michael, Scholl, Sebastian, Wolf, Hans-Heinrich, Hähling, Detlev, Hegenbart, Ute, Peter, Norma, Schulze, Antje, Florschütz, Axel, Schmidt, Volker, Reifenrath, Kolja, Zojer, Niklas, Junghanss, Christian, Sayer, Herbert G., Maschmeyer, Georg, Späth, Christian, Hochhaus, Andreas, Fischer, Thomas, Al-Ali, Haifa Kathrin, and Niederwieser, Dietger

Published
2021
Full Text
View/download PDF

9. Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Author

Heinicke, Thomas, Krahl, Rainer, Kahl, Christoph, Cross, Michael, Scholl, Sebastian, Wolf, Hans‑Heinrich, Hähling, Detlev, Hegenbart, Ute, Peter, Norma, Schulze, Antje, Florschütz, Axel, Schmidt, Volker, Reifenrath, Kolja, Zojer, Niklas, Junghanss, Christian, Sayer, Herbert G., Maschmeyer, Georg, Späth, Christian, Hochhaus, Andreas, Fischer, Thomas, Al‑Ali, Haifa Kathrin, and Niederwieser, Dietger

Published
2021
Full Text
View/download PDF

10. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation

Author

Schmidt, Volker, Niederwieser, Dietger, Schenk, Thomas, Behre, Gerhard, Klink, Anne, Pfrepper, Christian, Hinke, Axel, Beelen, Dietrich W., Junghanss, Christian, Uharek, Lutz, Krüger, William H., Hochhaus, Andreas, Sayer, Herbert G., and for the East German Study Group for Hematology and Oncology (OSHO)

Published
2018
Full Text
View/download PDF

14. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Author

Jaramillo Segura, Sonia, Wass, Maxi, Schaffrath, Judith, Rieger, Kathrin, Nogai, Axel, Haenel, Mathias, Herbst, Regina, Stoelzel, Friedrich, Röllig, Christoph, Jost, Edgar, Schlenk, Richard F., Noppeney, Richard, Brandts, Christian H., Krug, Utz, Goetze, Katharina S., Buske, Sebastian, Florschütz, Axel, Schubert, Jörg, Opitz, Bernhard, Mohren, Martin, Eßeling, Eva, von Witzendorff, Stephan, Subklewe, Marion, Kaufmann, Martin, Frickhofen, Norbert, Scholz, Christian W, Schäfer-Eckart, Kerstin, Kunzmann, Volker, Schmidt-Hieber, Martin, Sayer, Herbert G., Rank, Andreas, Hemmati, Philipp, Schueler, Frank, Kowoll, Simone, Scheller, Marina, Steighardt, Jörg, Edemir, Bayram, Mueller, Lutz Peter, Gliko-Kabir, Irit, Ludwig-Kraus, Beatrice, Edemir, Sabine, Sorani, Ella, Binder, Mascha, Vainstein, Abi, Kadosh, Shaul, Gromann, Cora, Wienke, Andreas, Baldus, Claudia D., Platzbecker, Uwe, Serve, Hubert, Bornhaeuser, Martin, Junghanss, Christian, and Mueller-Tidow, Carsten

Published
2022
Full Text
View/download PDF

15. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation

Author

Pfrepper, Christian, Klink, Anne, Behre, Gerhard, Schenk, Thomas, Franke, Georg-Nikolaus, Jentzsch, Madlen, Schwind, Sebastian, Al-Ali, Haifa-Kathrin, Hochhaus, Andreas, Niederwieser, Dietger, and Sayer, Herbert Gottfried

Published
2016
Full Text
View/download PDF

17. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

Author

Pfirrmann, Markus, Saussele, Susanne, Hochhaus, Andreas, Reiter, Andreas, Berger, Ute, Hossfeld, Dieter K., Nerl, Christoph, Scheid, Christof, Spiekermann, Karsten, Mayer, Jiri, Hellmann, Andrzej, Lechner, Klaus, Falge, Christiane, Sayer, Herbert G., Bunjes, Donald, Ganser, Arnold, Beelen, Dietrich W., Baldomero, Helen, Schanz, Urs, Heimpel, Hermann, Kolb, Hans-Jochem, Hasford, Joerg, Gratwohl, Alois, Hehlmann, Rüdiger, and for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group

Published
2014
Full Text
View/download PDF

23. Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort.

Author

Brioli, Annamaria, Nägler, Theresa Maria, Yomade, Olaposi, Rüthrich, Maria Madeleine, Scholl, Sebastian, Frietsch, Jochen J., Hilgendorf, Inken, Ernst, Thomas, Sayer, Herbert Gottfried, Hochhaus, Andreas, Mügge, Lars-Olof, and von Lilienfeld-Toal, Marie

Subjects
MULTIPLE myeloma, BIOLOGY, STEM cell transplantation, AUTOTRANSPLANTATION, CORONARY disease, MONOCLONAL gammopathies, PLASMA cell diseases
Abstract

Introduction: Multiple myeloma (MM) is a plasma cell disease that affects more men than women. Although there is an obvious imbalance in incidence, knowledge of differences in biology and outcome between the sexes is surprisingly rare. Methods: We performed a unicentric retrospective analysis of patients with MM treated at a tertiary cancer centre between 2003 and 2018. Results: We present a sex-disaggregated analysis of the characteristics and outcome of MM in a cohort of 655 patients (median age at diagnosis 62 years; 363 men with a median age at diagnosis 62 years and 292 women with a median age at diagnosis 63 years, p = 0.086). Most patients (n = 561, 86%) received myeloma-specific treatment. Median overall survival was 76 months (95% CI 63–89) (72 months in men [95% CI 54–90] and 83 months in women [95% CI 66–100], p = ns). Apart from a higher incidence of moderate and severe anaemia in women (p < 0.001), there were no statistically significant differences in the biology of the underlying MM. Similarly, in the group of patients who received high-dose therapy with autologous stem-cell transplantation (ASCT, n = 313), no statistically significant differences apart from more frequent anaemia in women were detected regarding the biology of the disease. However, there was a trend toward a higher plasma cell infiltration of the bone marrow and toward more frequent high-risk features in women. In contrast, relevant comorbidities were significantly more common in men (for example, coronary heart disease in 13% of men vs. 2% of women, p < 0.001). Toxicities after ASCT were not significantly different between the sexes with the exception of severe mucositis, which occurred in 22% of men versus 40% of women (p = 0.001). Conclusion: In conclusion, this first sex-disaggregated analysis of MM patients in Germany supports previous findings that survival is comparable amongst sexes, but women experience more toxicity of high-dose therapy. The higher incidence of clinically relevant anaemia in women warrants further investigation to exclude underlying treatable causes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

Author

Kröger, Nicolaus, Shaw, Bronwen, Iacobelli, Simona, Zabelina, Tatjana, Peggs, Karl, Shimoni, Avichai, Nagler, Arnon, Binder, Thomas, Eiermann, Thomas, Madrigal, Alejandro, Schwerdtfeger, Rainer, Kiehl, Michael, Sayer, Herbert Gottfried, Beyer, Jörg, Bornhäuser, Martin, Ayuk, Francis, Zander, Axel Rolf, and Marks, David I.

Published
2005

37. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

Author

Kröger, Nicolaus, Schilling, Georgia, Einsele, Hermann, Liebisch, Peter, Shimoni, Avichai, Nagler, Arnon, Perez-Simon, Jose A., San Miguel, Jesus F., Kiehl, Michael, Fauser, Axel, Schwerdtfeger, Rainer, Wandt, Hannes, Sayer, Herbert G., Myint, Han, Klingemann, Hans, Zabelina, Tatjana, Dierlamm, Judith, Hinke, Axel, and Zander, Axel R.

Published
2004
Full Text
View/download PDF

38. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

Author

Kröger, Nicolaus, Perez-Simon, Jose A., Myint, Han, Klingemann, Hans, Shimoni, Avichai, Nagler, Arnon, Martino, Rodrigo, Alegre, Adrian, Tomas, Jose F., Schwerdtfeger, Rainer, Kiehl, Michael, Fauser, Axel, Sayer, Herbert Gottfried, Leon, Angel, Beyer, Jörg, Zabelina, Tatjana, Ayuk, Francis, San Miguel, Jesus F., Brand, Ronald, and Zander, Axel Rolf

Published
2004
Full Text
View/download PDF

43. Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.

Author

Straka, Christian, Salwender, Hans, Knop, Stefan, Vogel, Martin, Müller, Jürgen, Metzner, Bernd, Langer, Christian, Sayer, Herbert, Jung, Wolfram, Dürk, Heinz A., Bassermann, Florian, Gramatzki, Martin, Rösler, Wolf, Wolf, Hans‐Heinrich, Brugger, Wolfram, Engelhardt, Monika, Fischer, Thomas, Liebisch, Peter, and Einsele, Hermann

Subjects
STEM cell transplantation, MULTIPLE myeloma, DIAGNOSIS, BORTEZOMIB, MELPHALAN
Abstract

Objective: A post hoc subgroup analysis of two phase III trials (NCT00416273, NCT00416208) was carried out to investigate the influence of 100/140 and 200 mg/m² melphalan as well as single/double autologous stem cell transplantation (ASCT) on progression‐free survival (PFS). Additionally, the effect of bortezomib consolidation on PFS was analyzed. Methods: Following induction therapy and high‐dose melphalan with subsequent ASCT, patients with newly diagnosed multiple myeloma (NDMM) were randomized 1:1 to either four 35‐day cycles of bortezomib consolidation (1.6 mg/m² IV on days 1, 8, 15, 22) or observation. Results: Of the 340 patients included in this analysis, 13.5% received 1 × MEL100/140, 22.9% 2 × MEL100/140, 31.2% 1 × MEL200, and 32.4% 2 × MEL200. With higher cumulative melphalan dose, PFS improved (P =.0085). PFS curves of patients treated with 2 × MEL100/140 and 1 × MEL200 were very similar. The superior dose effect of MEL200 over MEL100/140 was non‐existent in the bortezomib consolidation arm but pronounced in the observation arm (P =.0015). Similarly, double ASCT was only beneficial in patients without bortezomib consolidation (P =.0569). Conclusions: Full dose melphalan and double transplantation seem advantageous only as long as patients are not receiving bortezomib consolidation afterwards. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Automated detection of residual cells after sex-mismatched stem-cell transplantation – evidence for presence of disease-marker negative residual cells

Author

Johannes Tilman, Sayer Herbert G, Gloria Alexander, Heller Anita, Starke Heike, Kroll Torsten, Hoffmann Martin, Hartmann Isabell, Erlecke Jörn, Claussen Uwe, Liehr Thomas, and Loncarevic Ivan F

Subjects
Genetics, QH426-470
Abstract

Abstract Background A new chimerism analysis based on automated interphase fluorescence in situ hybridization (FISH) evaluation was established to detect residual cells after allogene sex-mismatched bone marrow or blood stem-cell transplantation. Cells of 58 patients were characterized as disease-associated due to presence of a bcr/abl-gene-fusion or a trisomy 8 and/or a simultaneous hybridization of gonosome-specific centromeric probes. The automatic slide scanning platform Metafer with its module MetaCyte was used to analyse 3,000 cells per sample. Results Overall 454 assays of 58 patients were analyzed. 13 of 58 patients showed residual recipient cells at one stage of more than 4% and 12 of 58 showed residual recipient cells less than 4%, respectively. As to be expected, patients of the latter group were associated with a higher survival rate (48 vs. 34 month). In only two of seven patients with disease-marker positive residual cells between 0.1–1.3% a relapse was observed. Besides, disease-marker negative residual cells were found in two patients without relapse at a rate of 2.8% and 3.3%, respectively. Conclusion The definite origin and meaning of disease-marker negative residual cells is still unclear. Overall, with the presented automatic chimerism analysis of interphase FISH slides, a sensitive method for detection of disease-marker positive residual cells is on hand.

Published
2009
Full Text
View/download PDF

47. Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.

Author

Straka, Christian, Knop, Stefan, Vogel, Martin, Müller, Jürgen, Kropff, Martin, Metzner, Bernd, Langer, Christian, Sayer, Herbert, Jung, Wolfram, Dürk, Heinz A., Salwender, Hans, Wandt, Hannes, Bassermann, Florian, Gramatzki, Martin, Rösler, Wolf, Wolf, Hans‐Heinrich, Brugger, Wolfram, Fischer, Thomas, Liebisch, Peter, and Engelhardt, Monika

Subjects
AUTOGRAFTS, MULTIPLE myeloma, OLDER patients, BORTEZOMIB, PLASMACYTOMA, STEM cell transplantation
Abstract

Objective: A post hoc analysis of two phase III trials was carried out to explore the influence of age and treatment factors on the effect of bortezomib consolidation on progression‐free survival (PFS) post autologous stem cell transplantation (ASCT). Methods: Patients with newly diagnosed multiple myeloma were assigned to one of two trials (ClinicalTrials.gov IDs: NCT00416273, NCT00416208), which were conducted in parallel, based on age (18‐60 or 61‐75 years, respectively). Following induction and ASCT, patients were randomized 1:1 to four 35‐day cycles of bortezomib consolidation (1.6 mg/m2 IV on days 1, 8, 15, 22) or observation only. Results: Median PFS with bortezomib consolidation vs observation was 33.6 vs 29.0 months (P = 0.3599) in patients aged 18‐60 years (n = 202), and 33.4 vs 26.4 months (P = 0.0073) in patients aged 61‐75 years (n = 155), respectively. Bortezomib consolidation post‐ASCT appeared to equalize outcomes between older and younger patients who received prior treatment of differing intensity. This suggests that the effect of consolidation may be relative and may depend on the composition and intensity of induction and high‐dose therapy. Conclusion: Older patients receiving less intensive prior treatment could experience a larger PFS benefit from bortezomib consolidation. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

49. Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Author

Niederwieser, Dietger, Krahl, Rainer, Kahl, Christoph, Wolf, Hans-Heinrich, Scholl, Sebastian, Cross, Michael, Hegenbart, Ute, Peter, Norma, Niederwieser, Christian, Florschütz, Axel, Reifenrath, Kolija, Zojer, Niklas, Jakob, Christian, Junghanss, Christian, Sayer, Herbert G., Schmidt, Volker, Schwind, Sebastian, Maschmeyer, Georg, Fischer, Thomas, Hochhaus, Andreas, Al-Ali, Haifa Kathrin, and Heinicke, Thomas

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results